Skip to main content

Articles

Page 207 of 209

  13. The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascula...

    Authors: Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto and Robert H Fagard
    Citation: Trials 2001 2:298
    Content type: Research Published on:

  21. Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overal...

    Authors: Jan Kristian Damås, Lars Gullestad and Pål Aukrust
    Citation: Trials 2001 2:271
    Content type: Review Published on:

  22. Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the f...

    Authors: Curt D Furberg and Bertram Pitt
    Citation: Trials 2001 2:205
    Content type: Commentary Published on:

  28. Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the lo...

    Authors: Walter Ageno and Menno V Huisman
    Citation: Trials 2001 2:233
    Content type: Review Published on:

  29. Cardiac rehabilitation (CR) is a commonly used treatment for men and women with cardiovascular disease. To date, no single study has conclusively demonstrated a comprehensive benefit of CR. Numerous individual...

    Authors: Scott A Lear and Andrew Ignaszewski
    Citation: Trials 2001 2:221
    Content type: Review Published on:

  33. Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high i...

    Authors: Thomas W Meade
    Citation: Trials 2001 2:195
    Content type: Research Published on:

  35. Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators...

    Authors: Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol…
    Citation: Trials 2001 2:187
    Content type: Research Published on:

  36. Clinical events committees (CEC) are used routinely to adjudicate suspected end-points in cardiovascular trials, but little information has been published about the various processes used. We reviewed results ...

    Authors: Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol…
    Citation: Trials 2001 2:180
    Content type: Research Published on:

  37. The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a prospective, randomized, multicenter clinical trial of carotid endarterectomy (CEA) versus carotid artery stenting (CAS) as preve...

    Authors: Robert W Hobson II, Virginia J Howard, Thomas G Brott, George Howard, Gary S Roubin and Robert DG Ferguson
    Citation: Trials 2001 2:160
    Content type: Commentary Published on:

  39. Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until...

    Authors: Vernon VS Bonarjee and Kenneth Dickstein
    Citation: Trials 2001 2:151
    Content type: Commentary Published on:

  42. Randomized trials and observational studies, such as case-control studies, are often seen as opposing approaches. However, in many instances results obtained by different designs may complement each other. For...

    Authors: Frits R Rosendaal
    Citation: Trials 2001 2:109
    Content type: Commentary Published on:

  44. Data quality assurance and quality control are critical to the effective conduct of a clinical trial. In the present commentary, we discuss our experience in a large, multicenter stroke trial. In addition to s...

    Authors: DeJuran Richardson and Shande Chen
    Citation: Trials 2001 2:115
    Content type: Commentary Published on:

  45. Women may be at increased risk for venous thromboembolism (VTE) as compared with men. We studied the effects of genetic and biochemical markers of thrombophilia in women, in conjunction with other established ...

    Authors: Joel G Ray, Loralie J Langman, Marian J Vermeulen, Jovan Evrovski, Erik L Yeo and David EC Cole
    Citation: Trials 2001 2:141
    Content type: Research Published on:

  49. During the past decade considerable research has been conducted into the use of cardiac troponins, their diagnostic capability and their potential to allow risk stratification in patients with acute chest pain...

    Authors: Britta U Goldmann, Robert H Christenson, Christian W Hamm, Thomas Meinertz and E Magnus Ohman
    Citation: Trials 2001 2:75
    Content type: Review Published on:

  50. Results from the recent Dietary Approaches to Stop Hypertension (DASH)-Sodium trial provide the latest evidence concerning the effects of dietary patterns and sodium intake on blood pressure. Participants ate ...

    Authors: William M Vollmer, Frank M Sacks and Laura P Svetkey
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:71
    Content type: Commentary Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    2.5 - 2-year Impact Factor
    2.5 - 5-year Impact Factor
    0.827 - SNIP (Source Normalized Impact per Paper)
    0.814 - SJR (SCImago Journal Rank)

    2023 Speed
    33 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    6,282,238 downloads
    5,569 Altmetric mentions

Trials

ISSN: 1745-6215